You are on the thresh hold of becoming a professional!

Aviation?

IT?

Pharma? Retail?

Insurance ?

Banking ?

Media?

Which Industry should you choose? Why?

Look no further..

The Employer of Choice

Indian pharma market, projected growth 11-13%* over next 3-5 years
Population dynamics Large population base 1.5 Bn by 2050 Increasing capacity to spend Literacy rate at 65-70% and estimated at 95% by

Increasing Life expectancy at birth, currently 65 and projected up to 69 by 2020.

Geriatric population to double over next 15 years High disease prevalence Fastest growing diabetes population AIDS, Oncology and other chronic ailments growing in numbers Improved awareness & detection levels

2020.
Huge middle class with buying capacity - 450 mio Opening up of reimbursement avenues Wave of shopping malls, credit uptake

Changing healthcare model Major pharma and insurance cos now in India Disease specific insurance plans in place Medical tourism growing by 20% YoY Corporatisation of hospitals and pharmacies Move to more scientific methods of promotion New distribution channels

Increased healthcare access yrs Improving access and growth rates in rural India Hospital market growing rapidly, ~30-40% QoQ

Current access ~40-50%; govt. committed to take it to 80% in next 15

OTC market projected to grow at 10% s

Indian Pharmaceutical Market

The Indian pharmaceutical market is expected to touch USD 40 billion by 2015 Indian pharma industry sales up 18 % despite recession and slowdown in March 2009 Indias Pharma sector ranks 3rd in terms of volume of production with 10% share of the global pharmaceutical market ORG projects the Indian pharmaceutical industry to grow at 15-20% over the next few years

Indias Position
India: 3rd Highest Contributor to Global Pharma Growth
196 $ Bn 20.0 14 14 23

20 15 10 5 0 2005 2015
7

CAGR 12%
6.3

14 13 12 11

Source: IMS World Review, McKinsey India Pharmaceutical Demand Model

Why Pharma ?
High Disease Prevalence Fastest growing diabetes population AIDS, Oncology and other chronic ailments growing Population Dynamics Large population base of 1.5 Billion by 2050

Geriatric population to double over next 15 years

Increased Healthcare Access Current access ~ 35%; government committed to take it to 80% in 15-20 years Improving access and growth rates in rural India

Increasing Capacity to Spend Huge middle class with vigorous buying capacity Opening up of reimbursement avenues

Changing Healthcare
Model Medical tourism growing by 20% Corporatization of hospitals and pharmacies New distribution channels

Why Pharma ?
Healthcare Sector remains insulated from global meltdown.

Pharma From Rs.20,000 Crs to Rs.35367 Crs forms the core of healthcare

Insurance From Rs.1004cr in 2004 to Rs 5125cr in (2008) @ CAGR 37%

Indian Healthcare Industry

Hospitals No. of beds ~9,14,543 Increase in Private Sector OTC Market Today > than Rs 3000 crs. has grown at 12-15%

Medical Tourism Risen from nothing, is today a $450 Mn industry. Infertility, Cardiac management are big contributors
Source: IMS World Review, McKinsey India Pharmaceutical Demand Model

Medical Devices Small but maturing market

Performance of different sectors

Industry

Aviation

Banking

IT

Pharma

Insurance

ITES

Media

Retail

-14.7%

-0.6%

-5.6%

9.8%

6.3%

-12.8%

3.8%

-2.1%

Source: Indiainfoline, Sector Updates, Jan 09 20

10 0 Aviation Banking IT Pharma Insurance ITES Media Retail

-10
-20

9.8% Pharma Continues to Shine

An overview of Indian Pharma Market

At Rs. 49900 Cr on retail, the industry recorded a value growth of 14%, far higher than previous year

Size & Growth

Growth Contributors

A change in trend, new introductions with 6% have dropped, while price increases contributed 2% with older products growing at 6%

Indian Vs MNC

Indian companies still dominate the market with a share of ~77.

Therapy Split
June MAT 11, SSA

Acute Therapies account for 73% of the MS growing at 13%, while chronic therapies are growing at 16%

Enter the world of GSK

THE WORLD OF GSK

Who we are ?
GlaxoSmithKline is one of the worlds leading research-based pharmaceutical and healthcare companies. Headquartered in the UK with major business operations in the US, we employ more than 99,000 people in 120 countries. With a firm foundation in science, we discover, develop, manufacture and distribute prescription medicines, vaccines and consumer healthcare products Have a challenging and inspiring mission to improve the quality of human life by enabling people to do more, feel better and live longer.

THE WORLD OF GSK

What we do ?
We discover, develop and market medicines and vaccines that meet patients needs. We also innovate and market consumer healthcare products that help people stay healthy. Our business comprises three main types of product: prescription medicines, vaccines and consumer healthcare products. Our products include treatments for a wide variety of diseases, conditions and illnesses.

MNC Ranking:

Rank

Company

Val in crs.

Val MS

Val Growth%

MNC ABBOTT* GLAXOSMITHKLINE* PFIZER* SANOFI AVENTIS* NOVARTIS INTL.*

11480 3452 2051 1545 1075 857

100% 30% 18% 13% 9% 7%

13 15 9 13 14 14

1 2 3 4 5

June MAT 11 , SSA

India Corporate Ranking : Vaccine Business

Companies Vaccines Market GSK Pharma Sanofi Aventis

Val in crs 890 203 181

Val MS (%) 100% 23% 20%

Novartis
Serum Inst. Pfizer

96
87 81

11%
10% 9%

Source: ORG ims Vaccines Audit: Mar MAT11

GSK leads!
General Practioner Consulting Physician Paediatricians Gynaecologists General Surgeons Dermatologists ENT Oncologists Cardiologists Chest Physicians Gastroenterologists Diabetologists
Source : Cmarc

Key Specialities

GSK Rank
1 1 1 1 1 1 1 1 3 2 3 3

Our Purpose

Our global quest is to improve the quality of human life by enabling people to do more, feel better and live longer

Our Mission and Strategy

Grow a diversified global business

Deliver more products of value

Simplify the operating model

Andrew Witty CEO

Overview
Key facts
2009 Revenue: Net income: 28,368 million 5,669 million

Company overview Employees: Countries: 99000 114

Headquarters: Brentford,London

More than 35 doses of vaccines distributed every second 8 million spent on R&D every day

Leader in the global respiratory segment

1100 prescriptions written for a GSK product every minute 7% of global pharmaceutical sales

Few Key Indicators :

Highlights

Net Sales growth at 13%

Sales
Trading Profit

Pharma Business 14%

Profit from Operations before Investment Income growth 14%

Profitability maintained at 35% PBT growth 14%

Profit

PAT but before exceptional items growth 15%

EPS after exceptional items `66.60; 15% growth before exceptional

EPS

Creating a broader portfolio of potential high value assets

New product contributions to growth in 2010 26% New Product contributions to Total Rx Sales 7%

2007

2008

2009

2010

A global leader
Britains most Admired Companies 2009 GlaxoSmithKline recognized as one of the 50 Best Employers in Canada Employees Choice 50 Best Places to Work, Glassdoor, 2010 Best Places to Work for LGBT Equality, Human Rights Campaign, 2010 For the 18th consecutive year named to the 100 Best Companies list by Working Mother magazine GlaxoSmithKline Receives Perfect Score on Corporate Equality Index GlaxoSmithKline was rated first in a Best Ethical Score category of the worlds 250 top companies both in the pharmaceutical category and across all categories Best Employer in Hungary, Slovakia, Czech Republic and Poland

Financial performance
EPS and Book Value per share
Book value EPS

68.6

46.8

52.9

59.6

161

182

207

228

Return on Average Net Worth and Average Capital Employed (%)

41.9 ` 40.1
RONW ROCE

40.8

2007

2008

2009

2010

39.9

31.5

31.1

30.9 30.6

2007

2008

2009

2010

GSK India
Established in 1924 Two large manufacturing sites at Thane (bulk drugs) and Nasik(formulations) GSK India is the number 3 ranked pharma company in the US$ 5 billion ethical pharmaceutical market Ranked No. 1 in corporate image by doctors in a survey by A C Nielsen ORG MARG Highest sales force productivity

GSK Corporate Office, Worli

GSK India - Board of Directors

D.S.Parekh Chairman & NonExecutive Director

Executive Directors
H. Joshipura Managing Director

Non -Executive Directors Independent Directors Independent Directors

R.R. Bajaaj M.B.Kapadia Sr. Executive Director

D. Sundaram

Dr. A. Banerjee Executive Director

V. Narayanan

A. Nimbalkar

N. Kaviratne R. Sequeira Executive Director P V Nayak V Thyagarajan Vice Chairman& Non Executive Director

GSK 5 Year Commercial Strategy.

Focus on GSK Power Brands

Organic Growth

In-licensing Opportunities

GSK India a partner of choice

Post 2007 New Launches Rotarix, Infanrix, Cervarix, Streptorix

Vx Portfolio Growth

2008 Launches : GSKs Wall - Oncology, Metabolic

New Patented Molecules

Yr-2010 Sales Ambition 2500 Cr from current 1500 Cr

CSR Initiatives
To lend a helping hand to the underserved in our society through support of women, children and the aged in the areas of health and education.

Ongoing Projects
Tribal Healthcare Project, Nashik Vocational Training Centers: Peth, Nashik Shelter Home for children in Behraich, U.P. Annual Support for Healthcare project in Kolkata Medical Healthcare Project at Deonar Dumping ground Mid-day Meal program 24/7 Helpline for the Aged

CSR Activities
New projects
Shelter Home in Jodhpur Nanhi Kali- Educating the girl child in Chattisgarh Support to Bhaktivedanta Hospital for early detection of Cancer Life Centre for learning disabilities

Global CSR Programs in India

The Lymphatic Filariasis (LF) Program The Personal Hygiene and Sanitation Education (PHASE) Program

Accolades!
2011
GSK India tops poll in Most Respected Companies survey GSK India has topped the pharmaceutical sector in this years survey of Most Respected Companies conducted by the countrys Business World magazine. GSK Indias efforts to create multiple channels of growth, which led to double-digit increases in both sales and profits, helped it top the poll. The company also scored highly in categories such as Innovation, Depth and Quality of Top Management, Ethics and Transparency, and Quality of Products and Services.

GSK India senior executive director, Mehernosh Kapadia, wins the Business Today Best CFO Award Mehernosh Kapadia, Senior Executive Director, was adjudged as the Best CFO in the Best Transformation Agent (Mid-size category). The awards considered those CFOs who best succeeded in finding the balance between company growth and meeting shareholder expectations during the difficult financial year of 2009-10.

Accolades!!
2010
GSK India senior executive director, Mehernosh Kapadia, wins coveted CFO award GSK India Senior Executive Director, Mehernosh Kapadia, has been voted Best Performing Chief Financial Officer (CFO) in the Pharmaceutical / Healthcare Sector at the CNBC-TV18 CFO Awards 2010. CNBC-TV18 is Indias biggest business channel and this is the fifth year that it has run its prestigious CFO awards programme, which recognises the wizards of the financial world who have not only demonstrated excellence through their sheer knowledge, vision and acumen, but also driven their businesses on a global platform.

2003
GlaxoSmithKline Pharmaceuticals limited voted the most respected pharmaceuticals company of India in a survey conducted by Business World-IMRB (Indian Market Research Market Bureau).

Employee Engagement
Empowerment League AAA Awards Wellness and Wellbeing Services Orange Day Corporate Sports Events Social Gatherings

Employee Engagement

Orange Day

Mental Health Day Womens Day Mumbai Marathon Dream Run

GSK Culture (High Performance Behaviour)

Innovative Thinking Information Search Creating Business Solutions Flexible Thinking

Engaging and Developing Others Building Relationships Teamwork Developing People Achieving Excellence Leading People Influence Building Confidence Communication Enable and Drive Change Continuous Improvement Customer Focus

Sales & Marketing.Do you have it in you??

Unique Role Characteristics
P&L responsibilities Initiative driven

Can be individualistic with high autonomy

High accountability Customer-facing Creativity and innovation required Focus on execution and delivery Strategic focus required Strong analytical skills, also intuition

Career Path for you

Managing Director

Commercial Director

Pharma / Marketing Director

Business Unit Head Business Development Manager

Marketing Manager Regional Business Head

Product Manager

Area Business Manager

We believe in investing in the BEST

Performance is the central theme to the GSK spirit. We firmly believe that superior performance merits superior reward, a belief that gives rise to our Total Reward Policy
We take Talent development seriously, and our sales force is the pride of the industry today. Initiatives like the GSK Academy help us in our commitment to growing talent from within GSK Great people do their best work at GSK every day

The Outcome is in your hands

It is not the strongest of the species that survive, nor the most intelligent, but the one most responsive to change.

- Charles Darwin